Max Healthcare inks pact for genomics research with Anuva

Max Healthcare inks pact for genomics research with Anuva

The pact involves Max Healthcare providing its expertise in clinical research along with a base for data and sample collection.

FPJ Web DeskUpdated: Tuesday, December 27, 2022, 10:13 PM IST
article-image

Max Healthcare and genomics biotech firm Anuva have joined forces to for genomic-based research focusing on communicable and non-communicable diseases in India, through an MoU. To be conducted over the next five years, the research will seek insights on application of precision medicine for breast cancer, lung cancer, diabetes, cardiac disease, kidney disease, and drug resistant tuberculosis, among others.

The pact involves Max Healthcare providing its expertise in clinical research along with a base for data and sample collection

Anuva provides translational research for a diverse genomic bio and data bank that will cater to Asian populations. The agreement also involves working on the possibility of conducting joint training, fellowships, exchange visits, knowledge and technology transfer.

RECENT STORIES

India’s Retail Inflation Set To Ease Further In October Below 0.5%, Supported By Food Price Drop...

India’s Retail Inflation Set To Ease Further In October Below 0.5%, Supported By Food Price Drop...

FPI Investment: Market Regains Momentum, Strong Inflows Of ₹21,167 Crore In October After Four...

FPI Investment: Market Regains Momentum, Strong Inflows Of ₹21,167 Crore In October After Four...

Record-Breaking Dhanteras Sales 2025, Indians Spend ₹1 Lakh Crore Despite Soaring Gold Prices

Record-Breaking Dhanteras Sales 2025, Indians Spend ₹1 Lakh Crore Despite Soaring Gold Prices

Reliance Industries to Begin Solar Power Generation Next Year From Mega 5,50,000-Acre Renewable...

Reliance Industries to Begin Solar Power Generation Next Year From Mega 5,50,000-Acre Renewable...

Foreign Portfolio Investors Return To Indian Markets With ₹6,480 Crore Inflows In October After...

Foreign Portfolio Investors Return To Indian Markets With ₹6,480 Crore Inflows In October After...